867144-27-2Relevant academic research and scientific papers
Direct catalytic enantioselective aza-Diels-Alder reactions
Sunden, Henrik,Ibrahem, Ismail,Eriksson, Lars,Cordova, Armando
, p. 4877 - 4880 (2005)
(Chemical Equation Presented) Proline and its derivatives catalyze the asymmetric one-pot three-component aza-Diels-Alder reaction between unmodified α,β-unsaturated cyclic ketones, aqueous formaldehyde, and aryl amines with excellent chemo- and enantiose
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Paragraph 0968, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist
Yang, Zunhua,Fang, Yuanying,Park, Haeil
, p. 2515 - 2519 (2017/05/10)
A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50
Direct asymmetric aza Diels-Alder reaction catalyzed by chiral 2-pyrrolidinecarboxylic acid ionic liquid
Zheng, Xin,Qian, Yunbo,Wang, Yongmei
experimental part, p. 567 - 570 (2010/08/05)
The utility of [EMIm][Pro] as an efficient catalyst for the one-pot direct asymmetric aza Diels-Alder reaction has been developed. A set of cyclic α,β-unsaturated ketones have been explored in up to 93% yield with up to >99/1 dr and >99% ee. Moreover, the catalytic system can be recycled and reused for six times without any significant loss of catalytic activity.
Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat
Coleman, Paul J.,Schreier, John D.,Roecker, Anthony J.,Mercer, Swati P.,McGaughey, Georgia B.,Cox, Christopher D.,Hartman, George D.,Harrell, C. Meacham,Reiss, Duane R.,Doran, Scott M.,Garson, Susan L.,Anderson, Wayne B.,Tang, Cuyue,Prueksaritanont, Thomayant,Winrow, Christopher J.,Renger, John J.
scheme or table, p. 4201 - 4205 (2010/08/22)
Orexins are excitatory neuropeptides that regulate arousal and sleep. Orexin receptor antagonists promote sleep and offer potential as a new therapy for the treatment of insomnia. In this Letter, we describe the synthesis of constrained diazepanes having
BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 43, (2008/06/13)
The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. T
